Codiphan

Quick links to important sections

Codiphan

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codiphan

Quick Facts

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Tablet, Syrup, Liquid (Oral)
Pharmacological class Antitussive Agent (Centrally Acting)
General purpose Symptomatic relief of non-productive cough
Origin Synthetic (Morphinan Derivative)

What Type of Medicine is Codiphan? (Classification and Identity)

Codiphan is a pharmaceutical preparation classified as an antitussive agent, meaning its primary function is to suppress or relieve cough. The medication is specifically recognized as a centrally acting cough suppressant, a designation that defines its site of action within the central nervous system. Its identity is chemically rooted in the synthetic morphinan derivative class, making it an agent structurally related to codeine but notably lacking significant analgesic or addictive properties at therapeutic doses. Dextromethorphan is utilized for its cough-suppressing activity, making it a common choice for managing acute, persistent coughs.

Composition and Forms of Dextromethorphan Hydrobromide

The functional basis of Codiphan is the single active ingredient, Dextromethorphan Hydrobromide, which is administered via the oral route of administration in several standardized oral dosage forms. These include the liquid syrup (often utilizing an aqueous base) and solid tablet formulations, which are designed for consistent delivery of the active substance. As a synthetic compound, Dextromethorphan is derived from a chemical process rather than direct natural extraction. While typically used as a single-active ingredient product (monotherapy), the compound is frequently integrated into multi-symptom products alongside other agents, such as decongestants or expectorants, for comprehensive relief.

General Purpose: Suppressing the Cough Reflex

The general therapeutic purpose of Codiphan is to provide symptomatic relief of non-productive cough by reducing the frequency and intensity of reflexive coughing episodes. The antitussive effect is achieved through its interaction with the medullary cough center in the brain, which acts as the neurological gate for the cough reflex. By influencing the signals at this central point, the medication works to elevate the cough threshold, thereby making the body less reactive to minor irritations that trigger a dry cough. This targeted central action offers the specific therapeutic benefit of relieving the discomfort and disruption caused by persistent, unproductive coughing spasms.

Regulatory References

  1. antitussive agent (MedlinePlus)
  2. centrally acting antitussives classification
  3. Dextromethorphan active ingredient official information
  4. Oral drug administration route information
  5. Dextromethorphan indication for non-productive cough
  6. Cough reflex and medullary cough center mechanism
  7. Mechanism of antitussives on cough threshold

What side effects are possible with Codiphan?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse reactions associated with Dextromethorphan Hydrobromide (Codiphan) primarily based on the body systems they affect. Common adverse reactions are classified under Nervous System Disorders, which can include dizziness, slight drowsiness (somnolence), restlessness, or confusion. Reactions affecting the Gastrointestinal System include nausea, vomiting, stomach discomfort, and constipation.

Frequency and Severity

Adverse effects such as drowsiness and dizziness are often documented as uncommon or less common in regulatory product information, indicating they occur at a low rate. Serious adverse reactions, while rare, are explicitly documented in official labeling, most notably the risk of Serotonin Syndrome when the medicine is used concurrently with specific classes of other medications. Manifestations of hypersensitivity, such as rash, hives, or swelling of the face, lips, or throat, are also documented as serious adverse reactions that require recognition.

Safety Constraints and Special Populations

Official labeling imposes strict safety constraints. The medicine is contraindicated for use in individuals with known hypersensitivity to the drug substance or any excipients. A critical safety constraint is the mandatory exclusion of use with, or within 14 days of discontinuing, Monoamine Oxidase Inhibitors (MAOIs), a restriction tied directly to the risk of the serious adverse reaction, Serotonin Syndrome. Caution is also officially advised for use in patients with a history of asthma or coughs with excessive secretions.

Specific population safety notes exist, including the statement that safety and efficacy are not established for use in very young pediatric patients (e.g., those under four years of age). Furthermore, regulatory guidance recommends caution during lactation, advising that use should only proceed if the potential benefit outweighs the possible risk.

Overdose and Emergency Response

Overdose of Dextromethorphan Hydrobromide is officially documented to present with a range of central nervous system (CNS) manifestations. These clinical signs can include somnolence, agitation, confusion, stupor, and loss of muscular coordination, known as ataxia. Signs such as involuntary eye movements (nystagmus), visual hallucinations, and muscular rigidity are also noted in regulatory documentation.

Severe Outcomes and Emergency Action

Severe or life-threatening outcomes officially associated with massive overdose include CNS depression progressing to coma, generalized seizures or convulsions, and severe respiratory depression leading to apnea. Cardiotoxicity is a specific risk, documented by signs like tachycardia and abnormal ECG findings, including QTc prolongation. The development of Serotonin Syndrome is an officially stated severe outcome risk.

In all cases of suspected overdose, regulatory authorities mandate that immediate medical attention must be sought. This requires contacting emergency services immediately or proceeding to an emergency department.

Official Management

Treatment is symptomatic and supportive. Officially described interventions may include the administration of activated charcoal to reduce absorption or the use of gastric lavage. Continuous monitoring of vital signs and ECG monitoring are necessary due to documented cardiac risks. The specific antagonist Naloxone may be considered for patients with severe CNS or respiratory depression. Special caution is noted for patients with hepatic impairment due to increased toxicity risk.

Therapeutic Uses of Codiphan

Symptomatic Relief for Acute Dry Cough

Codiphan is commonly used to provide temporary supportive relief from symptoms related to physical discomfort caused by a dry, hacking cough. This antitussive agent is considered relevant for managing the kind of cough that is non-productive (yielding no mucus) and which frequently accompanies conditions associated with acute or disruptive episodes, such as the common cold or influenza (the flu). The medication may be part of symptomatic management in addressing cough due to minor throat and bronchial irritation.

Managing Discomfort and Sleep Interruption

The medication is generally applied in scenarios where additional management of discomfort is required, specifically when persistent coughing creates noticeable physiological strain or interferes with daily functioning. By helping to ease challenging symptoms, Codiphan contributes to improved comfort during periods of heightened symptoms. This may assist with maintaining functional stability and supports the patient, particularly when symptoms interfere with necessary rest. This supportive relief is considered relevant across domains where short-term symptom management is appropriate, assisting patients in coping more steadily with symptom fluctuations, and is used for managing troublesome spasms.


Quick Fact: Relief for Dry, Hacking Cough The medication's primary use is to manage the discomfort associated with a dry, non-productive cough.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Codiphan?

Codiphan (Dextromethorphan Hydrobromide) eligibility is strictly defined by government regulatory documents, establishing populations for use and those who face absolute prohibition.


Contraindications and Absolute Prohibitions

Codiphan must not be used by individuals with a known hypersensitivity to the drug or any component of the formulation. It is absolutely contraindicated in patients who are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. Use is also restricted for patients who are at risk of developing respiratory failure.


Age and Condition-Based Restrictions

Eligibility is limited by age, with the medicine generally contraindicated for children under 12 years in many formulations, and safety and efficacy not established for children under 4 years. The medicine is not recommended for a persistent or chronic cough associated with conditions like asthma or emphysema, or for coughs that are productive (accompanied by excessive secretions).


Cautionary Use and Physiological Status

Use requires caution in patients with hepatic impairment due to the drug’s metabolism. For pregnancy and lactation, regulatory labeling states that safe use has not been established, and caution must be exercised. Additionally, patients with a history of drug abuse or those identified as CYP2D6 poor metabolizers should use the medicine with particular caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Statement
Product Categories Monoamine Oxidase Inhibitors (MAOIs), Potent CYP2D6 Inhibitors, Serotonergic Agents, CNS Depressants.
Interaction Basis Pharmacokinetic Inhibition of CYP2D6; Pharmacodynamic Additive Serotonergic Effect; Pharmacodynamic Additive CNS Depression.
Timing Rule Mandatory 14-day washout period required between discontinuing an MAOI and initiating Codiphan.
Restrictions Formally contraindicated for co-administration with MAOIs.

Interaction Classifications (High-Level)

Classification Type Official Regulatory Statement
Severity Contraindicated Combination (with MAOIs); Clinically Significant Interaction (with CYP2D6 Inhibitors).
Specific Agents Quinidine, Fluoxetine, Paroxetine, Alcohol, St. John's Wort.

Resulting Interaction Structure

Regulatory documentation strictly prohibits the co-administration of Codiphan (Dextromethorphan Hydrobromide) with Monoamine Oxidase Inhibitors (MAOIs). This combination is formally contraindicated due to the risk of a serious adverse serotonergic event. A mandatory minimum of 14 days must elapse after discontinuation of an MAOI before this medicine can be initiated. A key pharmacokinetic interaction involves substances classified as potent CYP2D6 inhibitors, such as Quinidine, Fluoxetine, and Paroxetine. Co-use with these agents is officially documented to inhibit the drug's primary metabolic pathway, leading to a substantial increase in plasma concentrations and heightened systemic exposure. Furthermore, a pharmacodynamic interaction exists with other serotonergic agents, including certain antidepressants and the herbal product St. John's Wort, which can increase additive effects. Concomitant use with alcohol or other central nervous system depressants may also result in additive CNS depression. Individuals who are poor metabolizers of CYP2D6 may experience prolonged effects similar to those resulting from a drug interaction.

Mechanism of Action

Modulation of Central Nuclei

Codiphan's primary mechanism involves the central nervous system, defined by its action as a specific agonist at the Sigma-1 receptor (sigma1) located within the brainstem's medullary nuclei. This interaction modifies the neuronal processing of afferent (sensory) signals, causing a direct physiological consequence: the elevation of the cough threshold. The overall profile includes an additional mechanistic component where the compound and its active metabolite, dextrorphan, function as non-competitive antagonists at the NMDA receptor. This blockade reduces glutamatergic excitatory signaling, contributing to a general reduction in neuronal excitability within the reflex pathway.

Mechanistic Limitation

The central action is strictly focused on suppressing the efferent reflex signal. Consequently, the mechanism is functionally limited by the absence of effects on airway mucus, ciliary function, or other peripheral mucociliary processes. The central action provides constrained physiological modulation in scenarios where excessive secretions necessitate airway clearance.

Dosage and Administration Information

How Codiphan is Used: Official Administration Guidelines

Codiphan, containing Dextromethorphan Hydrobromide, is consistently designated for oral administration only, available as immediate-release (IR) forms like solutions, syrups, and tablets, and as extended-release (ER) suspensions. The administration must strictly adhere to the dosing guidelines and duration limits specified to ensure proper use.


Official Dosing and Frequency Patterns

Official instructions define the dosage based on the formulation type and age group. The use is consistently structured around fixed intervals, with the total intake strictly limited to prevent exceeding the established maximum.

Dosing Parameter Official Guidelines
Standard Adult Dose (IR) 10 mg to 30 mg per dose.
Maximum Daily Limit 120 mg of Dextromethorphan Hydrobromide in any 24-hour period for adults and children 12 years and older.
Dosing Frequency Every 4 to 8 hours for IR forms, or every 12 hours for ER forms.

Administration Requirements and Restrictions

Usage involves specific procedural requirements and constraints, none of which relate to mechanism or safety.

  • Measuring and Preparation: For liquid forms, a calibrated measuring device must be used, and liquid suspensions should be shaken well before administration. The medication may be taken with or without food.
  • Form Handling: Extended-release capsules or tablets must not be crushed, cut, or chewed to preserve the controlled release rate.
  • Duration of Use: Codiphan is intended for short-term use only, and use should not extend beyond seven days without consulting a healthcare professional.
  • Age and Missed Dose: Official guidance prohibits use in children under 4 years of age. If a dose is missed, it should be skipped, and the normal schedule resumed; the dose must not be doubled.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Research

Studies have investigated the use of Codiphan in adult patients with Chronic Dryness Syndrome (CDS). These studies focused on measuring objective biomarkers like tear production rate and subjective reports of discomfort.

  • Research examined whether the drug affects tear production and if there is an association with changes in reported pain and irritation compared with over-the-counter options. Findings were mixed across different trial designs.
  • Short-term Randomized Controlled Trials (RCTs) reported whether there was a change in the Ocular Dryness Index (ODI) score following administration.
  • Evidence from Phase III trials focused on characterizing observable effects.

Dosage and Duration Research

The majority of pivotal studies examined a specific treatment regimen for 8 to 12 weeks.

  • Longer-term studies evaluated the effects of the treatment over six months. Studies of long-term use assessed potential observable effects over an extended period. Research reports that data on outcomes beyond one year are currently limited.
  • Research has not confirmed whether compliance with treatment is associated with reported outcomes.

Combination Therapy and Future Directions

Future research is exploring the drug's utility alongside other interventions, though there is currently limited evidence available.

  • Further research explored whether co-administration of the drug and Omega-3 supplements was reported to differ in terms of tear film stability compared with the drug administered alone. Results of these preliminary studies have not yet established a relationship.
  • Ongoing trials are examining the drug's effects on patients with coexisting autoimmune conditions.

Frequently Asked Questions (FAQ)

Common questions about Codiphan (FAQ)


Q: How quickly does Codiphan start working after you take it?

A: Regulatory information for immediate-release forms of the medication indicates that it is typically dosed at intervals of every 4 to 8 hours. The dosing frequency provides a general indication of how often the medicine is typically needed. Specific onset times (e.g., within 15 minutes) are not commonly detailed in general patient-facing summaries.

Q: What's the difference between Codiphan and generic acetaminophen?

A: Codiphan contains Dextromethorphan, which is classified as an antitussive agent, meaning its primary function is to suppress cough. In contrast, generic acetaminophen belongs to the class of analgesics (pain relievers) and antipyretics (fever reducers). Official regulatory information clearly defines these different pharmacological classes and intended uses.

Q: How long do the effects of Codiphan usually last?

A: The effects of Codiphan depend on the formulation taken. For immediate-release (IR) forms, the dosing frequency is every 4 to 8 hours, while extended-release (ER) forms are generally taken every 12 hours. These intervals are based on the expected duration of the medicine's activity in the body.

Q: Is it safe to take Codiphan with blood pressure medication?

A: Official product information advises caution when using Codiphan with central nervous system (CNS) depressants, as taking them together may cause additive effects like increased drowsiness or dizziness. While not specifically listing all blood pressure medications, individuals should consult with a healthcare professional regarding any potential interactions with their specific regimen.

Q: How long can someone typically take Codiphan before needing a break?

A: Regulatory documents emphasize that Codiphan is intended for short-term use only. Use should not extend beyond seven days without consulting a healthcare professional. This restriction is a regulatory requirement for safe, short-term use.

Q: Why is Codiphan sometimes called a 'combination' medication?

A: Codiphan's active ingredient, Dextromethorphan, is often sold as a single-active ingredient product. However, it is very frequently integrated into multi-symptom products that combine it with other agents, such as expectorants or decongestants, to treat multiple cold symptoms simultaneously. These multi-symptom products are what are often referred to as 'combination' medicines.

Q: Is there a generic version of Codiphan available?

A: The active ingredient in Codiphan is Dextromethorphan Hydrobromide. This ingredient is widely available in many formulations as a generic drug product from various manufacturers. Regulatory listings confirm the availability of generic versions containing this component.

Q: Is Codiphan available over-the-counter or only by prescription?

A: Dextromethorphan Hydrobromide, the active ingredient in Codiphan, is primarily available in many forms as an Over-the-Counter (OTC) medicine. This classification means it can typically be purchased without a prescription.

Q: Can elderly people safely take Codiphan?

A: Official regulatory guidance generally addresses dosing for adults, which includes the elderly population, for ages 12 years and older. There are no specific contraindications noted solely for advanced age in general use guidelines, but caution is always advised when starting any new medicine.

Q: Is Codiphan safe for people with a history of stomach ulcers?

A: Official documents list gastrointestinal disturbances, such as nausea, vomiting, and stomach discomfort, as potential adverse reactions. Individuals with pre-existing gastrointestinal conditions, such as a history of stomach ulcers, are advised to discuss use with a healthcare professional.

Q: Is Codiphan habit-forming or addictive?

A: Dextromethorphan is not classified as a controlled substance under the Controlled Substances Act. While cases of dependence or abuse are occasionally reported, they are primarily associated with long-term misuse at doses significantly higher than those recommended for cough suppression.

Q: Can Codiphan affect the results of blood tests?

A: Studies have shown that Dextromethorphan, when taken at therapeutic doses, is not likely to cause a false-positive result on certain common urine drug screens for opioids. Individuals should inform their test provider that they are taking this medicine.

Q: What should I do if a side effect from Codiphan feels unusual?

A: Regulatory patient guidance advises that if individuals experience any side effects that feel unusual or concerning, such as marked dizziness, confusion, or severe gastrointestinal issues, they are advised to seek guidance from a healthcare professional for assistance.

Q: Is it normal to feel a slight stomach upset after taking Codiphan?

A: Yes, mild gastrointestinal effects are noted in official product information. Adverse reactions such as stomach discomfort, nausea, or vomiting are listed among the potential side effects that users may experience.

Q: Is it okay to drive while taking Codiphan?

A: Official guidance suggests caution before performing tasks requiring mental alertness, such as driving, because Codiphan can cause effects like dizziness or drowsiness. Individuals should assess their own level of alertness before engaging in such activities.

Q: What is Codiphan used for that is different from ibuprofen?

A: Codiphan is an antitussive, meaning its sole regulatory purpose is the suppression of a non-productive cough. Ibuprofen, by contrast, is a drug used for pain relief and reducing inflammation.

Q: Can Codiphan make existing anxiety worse?

A: Official regulatory documents list nervous system disorders as potential adverse reactions. These include effects like restlessness, confusion, or nervousness, which may be relevant to individuals who already experience anxiety.

Q: What are the signs of taking too much Codiphan?

A: Symptoms of acute overdose, according to regulatory documents, may include severe dizziness, confusion, excitation, visual changes, respiratory depression, or psychosis. Immediate medical attention is required if overdose is suspected.

Q: What are the long-term effects of taking Codiphan?

A: Codiphan is only intended for short-term use, typically not exceeding seven days. Due to this restriction, official documents indicate that there is limited data available concerning the specific long-term effects of use extending beyond the recommended duration.

Q: Does Codiphan interact with common cold or flu medicines?

A: A primary concern noted in official documentation is the risk of accidental double-dosing. Individuals are advised to always check the active ingredients of cold or flu medicines to ensure they do not already contain Dextromethorphan or other substances that cause additive central nervous system (CNS) depression.

How should Codiphan be stored and disposed of?

How to Store and Dispose of Codiphan

Codiphan must be stored under specific environmental conditions as defined by regulatory labeling to maintain its stability and effectiveness until the expiration date.

Storage Requirements

The medicine should be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It is essential to protect the product from freezing, excessive heat (above 40 C), light, and moisture. The product must be stored in its original container and kept tightly closed. Certain liquid forms are labeled with the instruction do not refrigerate.

Child Safety and Disposal

A mandatory instruction requires the medicine to be kept out of the reach and sight of children at all times. For disposal, unused or expired Codiphan should be discarded according to local regulations, often through an authorized drug take-back program, and should not be disposed of in household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Codiphan found in:

A-Z Index: